Balanced Expectations Amid Challenges and Opportunities for Johnson & Johnson: Hold Rating Issued
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...
Becker's Spine Review1d
5 medtech notes: Medtronic, Johnson and Johnson and more
From new leadership to product launches, here are five key updates from spine and orthopedic devicemakers since Jan. 15.
Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance
Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...
Cautious Optimism: Evaluating Johnson & Johnson’s Hold Rating Amid ITCI Acquisition Uncertainties
Wells Fargo analyst Larry Biegelsen has maintained their neutral stance on JNJ stock, giving a Hold rating yesterday.Stay Ahead of the ...
Johnson & Johnson Acquires Intra-Cellular in $14.6 Billion Deal
Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...